Warfarin in haemodialysis patients with atrial fibrillation: What benefit?

Felix Yang, Denise Chou, Paul Schweitzer, Sam Hanon

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations

Abstract

Warfarin is commonly used to prevent stroke in patients with atrial fibrillation; however, patients on haemodialysis may not derive the same benefit from warfarin as the general population. There are no randomized controlled studies in dialysis patients which demonstrate the efficacy of warfarin in preventing stroke. In fact, warfarin places the dialysis patient at increased risk for haemorrhagic stroke and possibly ischaemic stroke. Additionally, warfarin increases the risk of major bleeding and has been associated with vascular calcification. Routine use of warfarin in dialysis for stroke prevention should be discouraged, and therapy should only be reserved for dialysis patients at high risk for thrombo-embolic stroke and carefully monitored if implemented. Published on behalf of the European Society of Cardiology.

Original languageEnglish
Pages (from-to)1666-1672
Number of pages7
JournalEuropace
Volume12
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

Keywords

  • Atrial fibrillation
  • Haemodialysis
  • Stroke

Fingerprint

Dive into the research topics of 'Warfarin in haemodialysis patients with atrial fibrillation: What benefit?'. Together they form a unique fingerprint.

Cite this